At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PSTV Plus Therapeutics, Inc.
Post-Market Trading 01-08 19:58:09 EST
1.20
-0.04
-3.23%
盘后1.22
+0.02+1.67%
19:11 EST
High1.35
Low1.15
Vol75.59K
Open1.32
D1 Closing1.24
Amplitude16.13%
Mkt Cap7.08M
Tradable Cap6.22M
Total Shares5.90M
T/O93.74K
T/O Rate1.46%
Tradable Shares5.19M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Plus Therapeutics expands strategic agreement with Telix IsoTherapeutics
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.